Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.
|2022-11-14 7:34:36 pm||Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q3 2022 Results - Earnings Call Transcript||SeekingAlpha|
|2022-11-14 1:1:0 pm||Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights||GlobeNewswire|
|2022-11-09 1:1:0 pm||Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference||GlobeNewswire|
|2022-11-07 1:1:0 pm||Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022||GlobeNewswire|
|2022-11-01 5:0:0 am||Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease||GlobeNewswire|
|2022-10-24 5:0:0 am||Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease||GlobeNewswire|
|2022-09-08 9:44:54 am||We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth||Simply Wall St.|